心痛舒联合瑞舒伐他汀治疗冠心病不稳定型心绞痛患者的疗效及对血脂和血清ET-1、NO的影响  

Curative Effect of Xintongshu Combined with Rosuvastatin and its Influences on Blood Lipid,Serum ET-1 and NO in Patients with Unstable Angina Pectoris of Coronary Heart Disease

作　　者：张翠翠 李红 王艳 ZHANG Cuicui;LI Hong;WANG Yan(Department of Pharmacy,Tangshan Hospital of Traditional Chinese Medicine,Tangshan 063000,China)

机构地区：[1]唐山市中医医院药学部,河北唐山063000

出　　处：《药物生物技术》2024年第3期276-280,共5页Pharmaceutical Biotechnology

基　　金：河北省中医药管理局科研计划项目(No.2022545)。

摘　　要：为了探究心痛舒联合瑞舒伐他汀治疗冠心病不稳定型心绞痛患者疗效及对血脂和血清内皮素-1(ET-1)、一氧化氮(NO)的影响,本研究选取2019年1月至2022年1月在河北唐山市中医医院接受治疗的108例冠心病不稳定型心绞痛患者,采用随机数表法将其分为常规组(瑞舒伐他汀治疗)和联合组(心痛舒联合瑞舒伐他汀治疗),两组患者均各54例。比较两组患者治疗的临床疗效和不良反应发生情况,比较两组患者治疗前和治疗30 d后的血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDLC)],血清超敏C反应蛋白(hs-CRP)、ET-1和NO水平,中医证候评分和超声心动图指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]。结果显示,联合组患者临床治疗总有效率比常规组高,差异有统计学意义(P<0.05)。治疗期间,联合组和常规组不良反应总发生率相当,差异无统计学意义(P>0.05)。治疗后,联合组患者的中医证候评分、LVEDD、LVESD、TC、TG、LDL-C、hs-CRP和ET-1水平均低于常规组,LVEF、HDL-C和NO高于常规组,差异有统计学意义(P<0.05)。心痛舒联合瑞舒伐他汀治疗冠心病不稳定型心绞痛疗效显著,能够降低患者血脂和炎症因子水平,改善血管内皮功能和心功能,缓解临床症状,且不增加不良反应发生率。To explore the curative effect of xintongshu combined with rosuvastatin and its influences on blood lipid,serum endothelin-1(ET-1)and nitric oxide(NO)in patients with unstable angina pectoris of coronary heart disease,a total of 108 patients with unstable angina pectoris of coronary heart disease who were treated in Tangshan Hospital of Traditional Chinese Medicine were enrolled as the research objects between January 2019 and January 2022.According to random number table method,they were divided into routine group(rosuvastatin treatment)and combination group(xintongshu combined with rosuvastatin treatment),54 cases in each group.The clinical curative effect and occurrence of adverse reactions,levels of blood lipid indexes[total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C)],serum hypersensitive C-reactive protein(hs-CRP),ET-1 and NO,scores of TCM syndromes and echocardiogram indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)]were compared between the two groups before and after treatment for 30 days.The total response rate of clinical treatment in combination group was higher than that in routine group(P<0.05).During treatment,the difference in total incidence of adverse reactions between combination group and routine group was not statistically significant(P>0.05).After treatment,scores of TCM syndromes,LVEDD,LVESD,TC,TG,LDL-C,hs-CRP and ET-1 levels in combination group were lower than those in routine group,while LVEF,HDL-C and NO levels were higher than those in routine group(P<0.05).The clinical curative effect of xintongshu combined with rosuvastatin is significant in patients with unstable angina pectoris of coronary heart disease,which can reduce levels of blood lipid and inflammatory factors,improve vascular endothelial function and cardiac function,and alleviate clinical symptoms,with low incidence of adverse reactions.

关 键 词：心痛舒 瑞舒伐他汀 冠心病 不稳定型心绞痛 血脂 血清内皮素-1 一氧化氮 

分 类 号：R541.4[医药卫生—心血管疾病]